Identification and characterization of human GDF15 knockouts.

Journal

Nature metabolism

ISSN: 2522-5812

Titre abrégé: Nat Metab

Pays: Germany

ID NLM: 101736592

Informations de publication

Date de publication:
26 Sep 2024

Historique:

received: 29 03 2024

accepted: 28 08 2024

medline: 27 9 2024

pubmed: 27 9 2024

entrez: 26 9 2024

Statut: aheadofprint

Résumé

Growth differentiation factor 15 (GDF15) is a secreted protein that regulates food intake, body weight and stress responses in pre-clinical models

Identifiants

DOI: 10.1038/s42255-024-01135-3 PMID: 39327531

pubmed: 39327531

doi: 10.1038/s42255-024-01135-3

pii: 10.1038/s42255-024-01135-3

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A. & Breit, S. N. The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018).

doi: 10.1016/j.cmet.2018.07.018 pubmed: 30184485

Benichou, O. et al. Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist. Cell Metab. 35, 274–286 e210 (2023).

doi: 10.1016/j.cmet.2022.12.011 pubmed: 36630958

Fejzo, M. et al. GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Nature https://doi.org/10.1038/s41586-023-06921-9 (2023).

doi: 10.1038/s41586-023-06921-9 pubmed: 38092039 pmcid: 10808057

Fejzo, M. S., Arzy, D., Tian, R., MacGibbon, K. W. & Mullin, P. M. Evidence GDF15 plays a role in familial and recurrent hyperemesis gravidarum. Geburtshilfe Frauenheilkd. 78, 866–870 (2018).

doi: 10.1055/a-0661-0287 pubmed: 30258246 pmcid: 6138473

Fejzo, M. S. et al. Analysis of GDF15 and IGFBP7 in hyperemesis gravidarum support causality. Geburtshilfe Frauenheilkd. 79, 382–388 (2019).

doi: 10.1055/a-0830-1346 pubmed: 31000883 pmcid: 6461465

Fejzo, M. S., MacGibbon, K. W., First, O., Quan, C. & Mullin, P. M. Whole-exome sequencing uncovers new variants in GDF15 associated with hyperemesis gravidarum. BJOG 129, 1845–1852 (2022).

doi: 10.1111/1471-0528.17129 pubmed: 35218128 pmcid: 9546032

Fejzo, M. S. et al. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat. Commun. 9, 1178 (2018).

doi: 10.1038/s41467-018-03258-0 pubmed: 29563502 pmcid: 5862842

Saleheen, D. et al. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature 544, 235–239 (2017).

doi: 10.1038/nature22034 pubmed: 28406212 pmcid: 5600291

Saleheen, D. et al. The Pakistan Risk of Myocardial Infarction Study: a resource for the study of genetic, lifestyle and other determinants of myocardial infarction in South Asia. Eur. J. Epidemiol. 24, 329–338 (2009).

doi: 10.1007/s10654-009-9334-y pubmed: 19404752 pmcid: 2697028

Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).

doi: 10.1056/NEJMoa2206038 pubmed: 35658024

Watanabe, H. & Oshima, T. The latest treatments for cancer cachexia: an overview. Anticancer Res. 43, 511–521 (2023).

doi: 10.21873/anticanres.16188 pubmed: 36697073

Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 23, 1150–1157 (2017).

doi: 10.1038/nm.4392 pubmed: 28846097

Emmerson, P. J. et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat. Med. 23, 1215–1219 (2017).

doi: 10.1038/nm.4393 pubmed: 28846098

Hsu, J. Y. et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 550, 255–259 (2017).

doi: 10.1038/nature24042 pubmed: 28953886

Tsai, V. W. et al. TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PLoS One 8, e55174 (2013).

doi: 10.1371/journal.pone.0055174 pubmed: 23468844 pmcid: 3585300

Johnen, H. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med. 13, 1333–1340 (2007).

doi: 10.1038/nm1677 pubmed: 17982462

Macia, L. et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS ONE 7, e34868 (2012).

doi: 10.1371/journal.pone.0034868 pubmed: 22514681 pmcid: 3325923

Chrysovergis, K. et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int J. Obes. 38, 1555–1564 (2014).

doi: 10.1038/ijo.2014.27

Coll, A. P. et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 578, 444–448 (2020).

doi: 10.1038/s41586-019-1911-y pubmed: 31875646

Patel, S. et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 29, 707–718 e708 (2019).

doi: 10.1016/j.cmet.2018.12.016 pubmed: 30639358 pmcid: 6408327

Breit, S. N., Brown, D. A. & Tsai, V. W. W. GDF15 analogs as obesity therapeutics. Cell Metab. 35, 227–228 (2023).

doi: 10.1016/j.cmet.2023.01.002 pubmed: 36754014

Breit, S. N., Brown, D. A. & Tsai, V. W. The GDF15-GFRAL pathway in health and metabolic disease: friend or foe? Annu Rev. Physiol. 83, 127–151 (2021).

doi: 10.1146/annurev-physiol-022020-045449 pubmed: 33228454

Wiklund, F. E. et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 9, 1057–1064 (2010).

doi: 10.1111/j.1474-9726.2010.00629.x pubmed: 20854422

Karusheva, Y. et al. The common H202D variant in GDF-15 does not affect its bioactivity but can significantly interfere with measurement of its circulating levels. J. Appl. Lab Med. 7, 1388–1400 (2022).

doi: 10.1093/jalm/jfac055 pubmed: 35796717

Graves, J. M. et al. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner. Am. J. Physiol. Heart Circ. Physiol. 320, H2283–H2294 (2021).

doi: 10.1152/ajpheart.00798.2020 pubmed: 33929896 pmcid: 8424547

Welsh, P. et al. Reference ranges for GDF-15, and risk factors associated with GDF-15, in a large general population cohort. Clin. Chem. Lab. Med. 60, 1820–1829 (2022).

doi: 10.1515/cclm-2022-0135 pubmed: 35976089 pmcid: 9524804

Crawford, J. et al. A phase Ib first-in-patient study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponsegromab in participants with cancer and cachexia. Clin. Cancer Res. 30, 489–497 (2024).

doi: 10.1158/1078-0432.CCR-23-1631 pubmed: 37982848

Groarke, J. D. et al. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. J. Cachexia Sarcopenia Muscle 15, 1054–1061 (2024).

doi: 10.1002/jcsm.13435 pubmed: 38500292 pmcid: 11154777

Klein, A. B. et al. Cross-species comparison of pregnancy-induced GDF15. Am. J. Physiol. Endocrinol. Metab. 325, E303–E309 (2023).

doi: 10.1152/ajpendo.00134.2023 pubmed: 37584611

Zeng, Y. T., Liu, W. F., Zheng, P. S. & Li, S. GDF15 deficiency hinders human trophoblast invasion to mediate pregnancy loss through downregulating Smad1/5 phosphorylation. iScience 26, 107902 (2023).

doi: 10.1016/j.isci.2023.107902 pubmed: 37766993 pmcid: 10520888

Szustakowski, J. D. et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat. Genet. 53, 942–948 (2021).

doi: 10.1038/s41588-021-00885-0 pubmed: 34183854

Mbatchou, J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 53, 1097–1103 (2021).

doi: 10.1038/s41588-021-00870-7 pubmed: 34017140

Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).

doi: 10.1093/bioinformatics/btq340 pubmed: 20616382 pmcid: 2922887

Seabold, S. & Perktold, J. Statsmodels: econometric and modeling with Python. In Proc. 9th Python in Science Conference (eds van der Walt, S. & Millman, J.) 57–61 (SciPy, 2010).